Dr. Vaishampayan on FGFR inhibitors and genetic testing in bladder cancer

Decipher genomic classifier shows prognostic value in intermediate-risk prostate cancer

Study identifies potential biomarkers for response to immunotherapy in urothelial carcinoma

Rapid genetic testing model found feasible for patients with prostate cancer

Study evaluates patient experiences with biopsy-based genomic testing during active surveillance

Study yields genetic clues to identifying aggressive prostate cancer in men of African ancestry

On-site genetic testing consults lead to higher testing completion rate, finds PCF-backed study

Decipher genomic classifier shows prognostic value in intermediate-risk prostate cancer

Study identifies potential biomarkers for response to immunotherapy in urothelial carcinoma

Rapid genetic testing model found feasible for patients with prostate cancer

Study evaluates patient experiences with biopsy-based genomic testing during active surveillance

Study yields genetic clues to identifying aggressive prostate cancer in men of African ancestry

On-site genetic testing consults lead to higher testing completion rate, finds PCF-backed study

Decipher genomic classifier shows prognostic value in intermediate-risk prostate cancer

Study identifies potential biomarkers for response to immunotherapy in urothelial carcinoma

Rapid genetic testing model found feasible for patients with prostate cancer

Study evaluates patient experiences with biopsy-based genomic testing during active surveillance

Study yields genetic clues to identifying aggressive prostate cancer in men of African ancestry

On-site genetic testing consults lead to higher testing completion rate, finds PCF-backed study

Related Content

Decipher genomic classifier shows prognostic value in intermediate-risk prostate cancer

The study assessed US veterans receiving care at the Veterans Health Administration for all cancer types, including prostate cancer.

Study identifies potential biomarkers for response to immunotherapy in urothelial carcinoma

Patients classified as GC high risk had a 5-year disease progression of 40%, compared with 20% among GC low-risk patients.

Rapid genetic testing model found feasible for patients with prostate cancer

The investigators identified several genetic factors, including ARID1A mutation, that correlated with survival outcomes in patients with advanced urothelial carcinoma treated with immune checkpoint blockade.

Study evaluates patient experiences with biopsy-based genomic testing during active surveillance

"In our sample, nearly 10% of patients [with prostate cancer] had a gene variant that made them eligible for effective new therapies, with faster results than traditional referral for genetic testing and counseling,” said Maria I. Carlo, MD.

Study yields genetic clues to identifying aggressive prostate cancer in men of African ancestry

Michael S. Leapman, MD, MHS, highlights a study of patient experiences with tissue-based genomic testing during active surveillance for prostate cancer.